用于人类的GLP-1药物正在对猫和狗进行测试,以便在美国和英国试验中治疗肥胖症和糖尿病。 GLP-1 drugs, used in humans, are being tested in cats and dogs to treat obesity and diabetes in U.S. and U.K. trials.

GLP-1体重损失药物在人类中很流行, 正在美国和英国试验中测试宠物, 重点是治疗猫和狗的肥胖症和糖尿病。 GLP-1 weight-loss drugs, popular in humans, are being tested for pets in U.S. and U.K. trials, with a focus on treating obesity and diabetes in cats and dogs. 奥卡瓦制药公司的一项试点研究正在测试一个为期六个月的猫植入器,而英国的一项称为MEOW-1的试验正在评估一个类似的超重猫注射剂。 A pilot study by Okava Pharmaceuticals is testing a six-month implant for cats, while a UK trial called MEOW-1 is evaluating a similar injectable for overweight cats. 这些治疗旨在减少胃口和缓慢消化,有可能降低成本,改善结果,而不是昂贵的非标签人类药物。 These treatments aim to reduce appetite and slow digestion, potentially lowering costs and improving outcomes compared to expensive off-label human drugs. 预计明年夏天将取得成果,希望为宠物肥胖提供负担得起的长期解决方案,这是与糖尿病和缩短寿命有关的日益严重的健康问题。 Results are expected next summer, with hopes of offering affordable, long-term solutions for pet obesity, a growing health concern linked to diabetes and shortened lifespans.